Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target.

Oncotarget - 1 Sept 2012

Zhang Fang, Rothermund Kristi, Gangadharan Sajithlal B, Pommier Yves, Prochownik Edward V, Lazo John S

Abstract excerpt

Cancer stem cells (CSCs) are a subpopulation generally thought to be responsible for cancer initiation and progression. Because CSCs are often rare in the total tumor cell population and differentiate rapidly when grown in culture, it has been challenging to uncover compounds that selectively tar...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Growth Processes
Share to DNA Topoisomerases, Type I
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Screening Assays

Share to MCF-7 Cells

Share to Molecular Targeted Therapy

Share to Neoplastic Stem Cells

Share to Topoisomerase I Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 22948175
DOI: 10.18632/oncotarget.632
PMCID: PMC3660065

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22948175-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target.PMID 22948175Read ↗

Using a Stem Cell–Based Signature to Guide Therapeutic Selection in CancerSemantic proximity Read ↗

A 1536-Well Quantitative High-Throughput Screen to Identify Compounds Targeting Cancer Stem CellsSemantic proximity Read ↗

Phenotypic High-Throughput Screening Elucidates Target Pathway in Breast Cancer Stem Cell–Like CellsSemantic proximity Read ↗

Exploring the cancer stem cell phenotype with high-throughput screening applications.Semantic proximity Read ↗

Identification of Breast Cancer Stem Cell Related Genes Using Functional Cellular Assays Combined With Single-Cell RNA Sequencing in MDA-MB-231 CellsSemantic proximity Read ↗

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput ScreeningSemantic proximity Read ↗

A ‘one-two punch’ therapy strategy to target chemoresistance in estrogen receptor positive breast cancerSemantic proximity Read ↗

Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalenceSemantic proximity Read ↗

A novel ALDH1A1 inhibitor blocks platinum-induced senescence and stemness in ovarian cancerSemantic proximity Read ↗

Drug Screening Identifies Niclosamide as an Inhibitor of Breast Cancer Stem-Like CellsSemantic proximity Read ↗

A genome‐wide RNAi screen reveals essential therapeutic targets of breast cancer stem cellsSemantic proximity Read ↗

Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.